(MedPage Today) — Enrollment jumps 13.8% nationwide
Uncategorized
Eyegate receives patent approvals for delivery system, pharmaceutical formulation
The U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application related to Eyegate Pharmaceuticals’ Eyegate II Delivery System with pre-filled drug applicator, the company announced in a press release.The patent is for a delivery device containing a hydrogel applicator used to transport therapeutic substance across and/or through the eye, the release said.
Uncategorized
Eleven Biotherapeutics completes patient enrollment for phase 3 study of isunakinra
Eleven Biotherapeutics has completed patient enrollment for the pivotal phase 3 study of isunakinra in patients with allergic conjunctivitis, the company announced in a press release. Isunakinra (EBI-005) is a topical interleukin-1 receptor blocker under study for use in moderate to severe allergic conjunctivitis. A total of 258 patients were randomized 1:1 to receive treatment with isunakinra or vehicle control in the multicenter, double-masked study. Safety and efficacy will be evaluated for up to 4½ weeks.
The end is in sight for reading glasses
A University of Leeds researcher is developing a new eye lens, made from the same material found in smartphone and TV screens, which could restore long-sightedness in older people.
Make the Diagnosis: Ocular Oddity
(MedPage Today) — Case Findings: A 45-year-old male presents with blurred vision in the left eye. He has no prior history of eye disease. The results of a fundoscopy showed lines of crystalline deposits following the path of the retinal arterioles.
…
Uncategorized
Inotek Pharmaceuticals Initiates Dosing of MATRx-1, the First Pivotal Phase 3 Clinical Trial of Trabodenoson, a Novel Treatment for Glaucoma
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Pharmaceuticals Initiates Dosing of MATRx- 1, the First Pivotal Phase 3 Clinical Trial of Trabodenoson, a Novel Treatment for Glaucoma